What is the brand name of vilazodone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vilazodone Brand Name

Vilazodone is marketed under the brand name Viibryd 1, 2, 3.

Product Details

Vilazodone hydrochloride is manufactured and marketed by Forest Pharmaceuticals (now part of Allergan/AbbVie) under the brand name Viibryd 2. The medication received FDA approval in 2011 for the treatment of major depressive disorder in adults 2, 3.

Available Formulations

Viibryd is available as film-coated tablets in three strengths 1:

  • 10 mg tablets: Pink colored, ellipse shaped, biconvex, debossed with "MV" on one side and "14" on the other 1
  • 20 mg tablets: Orange colored, ellipse shaped, biconvex, debossed with "MV" on one side and "15" on the other 1
  • 40 mg tablets: Blue colored, ellipse shaped, biconvex, debossed with "MV" on one side and "16" on the other 1

Mechanism of Action

Vilazodone is classified as a dual-acting serotonergic agent that combines selective serotonin reuptake inhibitor (SSRI) properties with partial 5-HT1A receptor agonist activity 1, 2, 4. This multimodal mechanism distinguishes it from traditional SSRIs, though the clinical significance of the 5-HT1A partial agonism remains under investigation 5.

References

Research

Vilazodone: a novel antidepressant.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012

Research

Vilazodone (Viibryd)--a new antidepressant.

The Medical letter on drugs and therapeutics, 2011

Research

Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.